Measurement of cartilage oligomeric matrix protein (COMP) in normal and diseased equine synovial fluids.

OBJECTIVE This study was designed to assay cartilage oligomeric matrix protein (COMP) in equine synovial fluids and to compare the concentration in synovial fluids from normal horses with joint diseased horses. The relationship between the COMP degradation and the matrix metalloproteinase activity in synovial fluids was also investigated. DESIGN Using COMP antigen prepared from equine articular cartilage and murine monoclonal antibody (12C4) raised against human COMP, an inhibition ELISA was developed. COMP in equine synovial fluids from normal and diseased joints was quantified. Metalloproteinase activities were evaluated in the same synovial fluids by a gelatin degradation ELISA. COMP fragments were evaluated qualitatively by Western blotting. RESULTS The COMP inhibition ELISA was reliable at concentrations of equine COMP between 62.5 and 2000 ng/ml. COMP values in joint fluids in both aseptic and septic joint disease (19.7+/-15.3 and 16.1+/-11.2 microg/ml, respectively) were significantly (P < 0.001) lower than normal (53.2+/-29.0 microg/ml). The molecular sizes of COMP on immunoblots were different between normal and diseased synovial fluids; more fragments were seen in diseased fluids. The aseptic (26.6 +/- 20.6%) and septic joint disease synovial fluids (36.1 +/- 37.5%) had significantly higher (P < 0.02 and 0.002, respectively) gelatinolytic activities than normal (13.6 +/- 13.7%). There was a negative correlation (R = -0.31, P < 0.002) between COMP level and gelatinase activity. Conclusions We conclude that the fragment pattern and the absolute COMP concentration maybe useful for monitoring joint disease, and that COMP degradation in synovial fluids from progressed joint disease may be due to MMP gelatinolytic activity.

[1]  M. Paulsson,et al.  Tendon extracellular matrix contains pentameric thrombospondin‐4 (TSP‐4) , 1995, FEBS letters.

[2]  P. Clegg,et al.  Matrix metalloproteinases 2 and 9 in equine synovial fluids. , 1997, Equine veterinary journal.

[3]  D. Heinegård,et al.  Cartilage matrix proteins. An acidic oligomeric protein (COMP) detected only in cartilage. , 1992, The Journal of biological chemistry.

[4]  T. Saxne,et al.  Increased serum concentrations of cartilage oligomeric matrix protein. A prognostic marker in early rheumatoid arthritis. , 1992, British journal of rheumatology.

[5]  D. Heinegård,et al.  Matrix proteins: potentials as body fluid markers of changes in the metabolism of cartilage and bone in arthritis. , 1995, The Journal of rheumatology. Supplement.

[6]  P. D. Di Cesare,et al.  Expression of cartilage oligomeric matrix protein by human synovium , 1997, FEBS letters.

[7]  M. Paulsson,et al.  Small fragments of cartilage oligomeric matrix protein in synovial fluid and serum as markers for cartilage degradation. , 1997, British journal of rheumatology.

[8]  J B Renner,et al.  Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity: the Johnston County Osteoarthritis Project. , 1999, Arthritis and rheumatism.

[9]  D. Heinegård,et al.  Bone scan and serum markers of bone and cartilage in patients with knee pain and osteoarthritis. , 1998, Osteoarthritis and cartilage.

[10]  G. N. Smith,et al.  Characterization of type V collagenase (gelatinase) in synovial fluid of patients with inflammatory arthritis. , 1992, The Journal of rheumatology.

[11]  E. Thonar,et al.  Characterization of monoclonal antibodies recognizing different fragments of cartilage oligomeric matrix protein in human body fluids. , 1997, Archives of biochemistry and biophysics.

[12]  C. McIlwraith,et al.  Joint disease in the horse , 1996 .

[13]  J Engel,et al.  Electron microscopy of native cartilage oligomeric matrix protein purified from the Swarm rat chondrosarcoma reveals a five-armed structure. , 1992, The Journal of biological chemistry.

[14]  D. Heinegård,et al.  Inhibition of interleukin-1alpha-induced cartilage oligomeric matrix protein degradation in bovine articular cartilage by matrix metalloproteinase inhibitors: potential role for matrix metalloproteinases in the generation of cartilage oligomeric matrix protein fragments in arthritic synovial fluid. , 1998, Arthritis and rheumatism.

[15]  D. Heinegård,et al.  The distribution of cartilage oligomeric matrix protein (COMP) in tendon and its variation with tendon site, age and load. , 1997, Matrix biology : journal of the International Society for Matrix Biology.

[16]  L. Lohmander,et al.  Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. , 1993, Arthritis and rheumatism.

[17]  R. Gay,et al.  Analysis of cartilage oligomeric matrix protein (COMP) in synovial fibroblasts and synovial fluids. , 1998, British journal of rheumatology.

[18]  D. Heinegård,et al.  COMP (cartilage oligomeric matrix protein) is structurally related to the thrombospondins. , 1992, The Journal of biological chemistry.

[19]  S. Jimenez,et al.  Production of cartilage oligomeric matrix protein (COMP) by cultured human dermal and synovial fibroblasts. , 1998, Osteoarthritis and cartilage.

[20]  D. Heinegård,et al.  Release of cartilage oligomeric matrix protein (COMP) into joint fluid after knee injury and in osteoarthritis. , 1994, Annals of the rheumatic diseases.

[21]  P. Dieppe,et al.  Variation of an epitope of keratan sulphate and total glycosaminoglycans in normal equine joints. , 1996, Equine veterinary journal.

[22]  P. Dieppe,et al.  Relationship between serum cartilage oligomeric matrix protein levels and disease progression in osteoarthritis of the knee joint. , 1995, British journal of rheumatology.

[23]  F. Breedveld,et al.  Activated gelatinase-B (MMP-9) and urokinase-type plasminogen activator in synovial fluids of patients with arthritis. Correlation with clinical and experimental variables of inflammation. , 1995, The Journal of rheumatology.

[24]  A. Poole,et al.  Changes in joint cartilage aggrecan after knee injury and in osteoarthritis. , 1999, Arthritis and rheumatism.

[25]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[26]  R. Todhunter,et al.  Concentrations of keratan sulfate in plasma and synovial fluid from clinically normal horses and horses with joint disease. , 1997, Journal of the American Veterinary Medical Association.

[27]  D. Heinegård,et al.  Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. , 1992, British journal of rheumatology.

[28]  M. Paulsson,et al.  Increased degradation and alteered tissue distribution of cartilage oligomeric matrix protein in human rheumatoid and osteoarthritic cartilage , 1996, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[29]  M. Paulsson,et al.  Cartilage oligomeric matrix protein: Isolation and characterization from human articular cartilage , 1995, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[30]  C. White,et al.  Regulation of cartilage oligomeric matrix protein synthesis in human synovial cells and articular chondrocytes. , 1998, Arthritis and rheumatism.

[31]  T. Saxne,et al.  Cartilage markers in synovial fluid in symptomatic knee osteoarthritis , 1997, Annals of the Rheumatic Diseases.

[32]  M. Paulsson,et al.  Cartilage oligomeric matrix protein (COMP) is an abundant component of tendon , 1994, FEBS letters.

[33]  C. Prange,et al.  Mutations in exon 17B of cartilage oligomeric matrix protein (COMP) cause pseudoachondroplasia , 1995, Nature Genetics.

[34]  S. Carter,et al.  Glycosaminoglycans in horses with osteoarthritis. , 1991, Equine veterinary journal.

[35]  D. Heinegård,et al.  Cartilage Oligomeric Matrix Protein Shows High Affinity Zinc-dependent Interaction with Triple Helical Collagen* , 1998, The Journal of Biological Chemistry.

[36]  M. Paulsson,et al.  Cartilage oligomeric matrix protein and thrombospondin 1. Purification from articular cartilage, electron microscopic structure, and chondrocyte binding. , 1994, European journal of biochemistry.

[37]  E. Thonar,et al.  Quantification of keratan sulfate in blood as a marker of cartilage catabolism. , 1985, The Journal of rheumatology.

[38]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[39]  M. Dougados,et al.  Serum biologic markers as predictors of disease progression in osteoarthritis of the knee. , 1997, Arthritis and rheumatism.

[40]  B. Månsson,et al.  Cartilage and bone macromolecules in knee joint synovial fluid in rheumatoid arthritis: relation to development of knee or hip joint destruction , 1997, Annals of the rheumatic diseases.